Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Methods

Published on 28 Apr 2023

HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer

in Cancer Molecular Targets and Therapeutics

Rubén Olivera-Salguero
Elia Seguí
Juan Miguel Cejalvo
Mafalda Oliveira
Pablo Tolosa
Maria Vidal
Marcos Malumbres
Joaquín Gavilá
Cristina Saura
Sonia Pernas

Frontiers in Oncology

doi 10.3389/fonc.2023.1151496

3,416 views
2 citations

Review

Published on 27 Apr 2023

Antibody-based cancer immunotherapy by targeting regulatory T cells

in Cancer Molecular Targets and Therapeutics

Quanxiao Li
Jun Lu
Jinyao Li
Baohong Zhang
Yanling Wu
Tianlei Ying

Frontiers in Oncology

doi 10.3389/fonc.2023.1157345

9,091 views
21 citations

Original Research

Published on 24 Apr 2023

ERBB family fusions are recurrent and actionable oncogenic targets across cancer types

in Cancer Molecular Targets and Therapeutics

Laura Schubert
Andrew Elliott
Anh T. Le
Adriana Estrada-Bernal
Robert C. Doebele
Emil Lou
Hossein Borghaei
Michael J. Demeure
Razelle Kurzrock
Joshua E. Reuss

Frontiers in Oncology

doi 10.3389/fonc.2023.1115405

6,753 views
8 citations

Hypothesis and Theory

Published on 24 Apr 2023

CCNF is a potential pancancer biomarker and immunotherapy target

in Cancer Molecular Targets and Therapeutics

Lifang Wei
Huiming Li
Mengjun Xiao
Cuiling Zhou
Jiliang Liu
Shilian Weng
Ruda Wei

Frontiers in Oncology

doi 10.3389/fonc.2023.1109378

3,826 views
1 citation

Case Report

Published on 21 Apr 2023

Coexistence of a novel STRN-ALK, NBEA-ALK double-fusion in an ovarian malignant mesothelioma patient: a case report and review

in Cancer Molecular Targets and Therapeutics

Xiao Wu
Qi Wang
Xiaohu Xu

Frontiers in Oncology

doi 10.3389/fonc.2023.1156329

1,919 views
2 citations

Case Report

Published on 20 Apr 2023

Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with LDLR-ROS1 fusion

in Cancer Molecular Targets and Therapeutics

Yun Shu
Zhouyu Wang
Hongjuan Shang
Wei Le
Yan Lei
Longzhang Huang
Liming Tao
Jun Chen
Jing Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1169876

1,883 views
1 citation

Original Research

Published on 19 Apr 2023

Zn-Co metal organic frameworks coated with chitosand and Au nanoparticles for chemo-photothermal-targeted combination therapy of liver cancer

in Cancer Molecular Targets and Therapeutics

Congling Yang
Santosh K. Tiwari
Lianshan Guo
Guanghui An
Heming Zheng
JianFeng Huang
Li Jiang
Zhihao Bai
Yanqiu Zhu
Nannan Wang

Frontiers in Oncology

doi 10.3389/fonc.2023.1110909

2,446 views
7 citations

Original Research

Published on 19 Apr 2023

Receptor–ligand pair typing and prognostic risk model of response or resistance to immune checkpoint inhibitors in lung adenocarcinoma

in Cancer Molecular Targets and Therapeutics

Shengqiang Mao
Lingyan Zeng
Ying Yang
Zhiqiang Liu
Li Zhang

Frontiers in Oncology

doi 10.3389/fonc.2023.1170942

2,161 views

Correction

Published on 13 Apr 2023

Corrigendum: Improving anti-tumor efficacy of low-dose Vincristine in rhabdomyosarcoma via the combination therapy with FOXM1 inhibitor RCM1

in Cancer Molecular Targets and Therapeutics

Johnny Donovan
Zicheng Deng
Fenghua Bian
Samriddhi Shukla
Jose Gomez-Arroyo
Donglu Shi
Vladimir V. Kalinichenko
Tanya V. Kalin

Frontiers in Oncology

doi 10.3389/fonc.2023.1163510

1,426 views
1 citation

Correction

Published on 12 Apr 2023

Corrigendum: The MYC paralog-PARP1 axis as a potential therapeutic target in MYC paralog-activated small cell lung cancer

in Cancer Molecular Targets and Therapeutics

Xing Bian
Xiaolin Wang
Qiuyan Zhang
Liying Ma
Guozhen Cao
Ao Xu
Jinhua Han
Jun Huang
Wenchu Lin

Frontiers in Oncology

doi 10.3389/fonc.2023.1192526

1,020 views

Original Research

Published on 11 Apr 2023

Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures

in Cancer Molecular Targets and Therapeutics

Joshua Alcaniz
Lars Winkler
Mathias Dahlmann
Michael Becker
Andrea Orthmann
Johannes Haybaeck
Stefanie Krassnig
Christina Skofler
Tobias Kratzsch
Susanne A. Kuhn

Frontiers in Oncology

doi 10.3389/fonc.2023.1129627

6,135 views
10 citations

Review

Published on 03 Apr 2023

UPS: Opportunities and challenges for gastric cancer treatment

in Cancer Molecular Targets and Therapeutics

Hang Yang
Huihan Ai
Jialin Zhang
Jie Ma
Kangdong Liu
Zhi Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1140452

3,824 views
3 citations

Original Research

Published on 03 Apr 2023

Synthetic oleanane triterpenoids suppress MYB oncogene activity and sensitize T-cell acute lymphoblastic leukemia cells to chemotherapy

in Cancer Molecular Targets and Therapeutics

Paloma Tejera Nevado
Tajana Tešan Tomić
Ali Atefyekta
André Fehr
Göran Stenman
Mattias K. Andersson

Frontiers in Oncology

doi 10.3389/fonc.2023.1126354

2,373 views
4 citations

Original Research

Published on 03 Apr 2023

Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer

in Cancer Molecular Targets and Therapeutics

Yanjie Han
Yuanyuan Xiong
Tao Lu
Rongrong Chen
Yuan Liu
Hui Tang
Ruixuan Geng
Yingyi Wang

Frontiers in Oncology

doi 10.3389/fonc.2023.1121708

3,946 views
3 citations

Case Report

Published on 30 Mar 2023

Case report: Obstructive jaundice caused by biliary cystadenoma

in Cancer Molecular Targets and Therapeutics

Yun-cheng Li
An-da Shi
Kang-shuai Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1165979

2,883 views
1 citation

Original Research

Published on 28 Mar 2023

Over-expression of RRM2 predicts adverse prognosis correlated with immune infiltrates: A potential biomarker for hepatocellular carcinoma

in Cancer Molecular Targets and Therapeutics

Zhongqiang Qin
Bo Xie
Jingyu Qian
Xiang Ma
Lan Zhang
Jianzhu Wei
Zhaoying Wang
Longfei Fan
Ziyi Zhu
Zhen Qian

Frontiers in Oncology

doi 10.3389/fonc.2023.1144269

3,142 views
9 citations

Navigation group

Articles

HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer

Antibody-based cancer immunotherapy by targeting regulatory T cells

ERBB family fusions are recurrent and actionable oncogenic targets across cancer types

CCNF is a potential pancancer biomarker and immunotherapy target

Coexistence of a novel STRN-ALK, NBEA-ALK double-fusion in an ovarian malignant mesothelioma patient: a case report and review

Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with LDLR-ROS1 fusion

Zn-Co metal organic frameworks coated with chitosand and Au nanoparticles for chemo-photothermal-targeted combination therapy of liver cancer

Receptor–ligand pair typing and prognostic risk model of response or resistance to immune checkpoint inhibitors in lung adenocarcinoma

Corrigendum: Improving anti-tumor efficacy of low-dose Vincristine in rhabdomyosarcoma via the combination therapy with FOXM1 inhibitor RCM1

Corrigendum: The MYC paralog-PARP1 axis as a potential therapeutic target in MYC paralog-activated small cell lung cancer

Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures

UPS: Opportunities and challenges for gastric cancer treatment

Synthetic oleanane triterpenoids suppress MYB oncogene activity and sensitize T-cell acute lymphoblastic leukemia cells to chemotherapy

Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer

Case report: Obstructive jaundice caused by biliary cystadenoma

Over-expression of RRM2 predicts adverse prognosis correlated with immune infiltrates: A potential biomarker for hepatocellular carcinoma